Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / COM
-
Shares outstanding
-
66.4M
-
Number of holders
-
116
-
Total 13F shares, excl. options
-
66.2M
-
Shares change
-
+5.95M
-
Total reported value, excl. options
-
$1.09B
-
Value change
-
+$94.9M
-
Put/Call ratio
-
0.18
-
Number of buys
-
70
-
Number of sells
-
-58
-
Price
-
$16.49
Significant Holders of RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) as of Q2 2023
159 filings reported holding RYTM - RHYTHM PHARMACEUTICALS, INC. - COM as of Q2 2023.
RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) has 116 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 66.2M shares
of 66.4M outstanding shares and own 99.72% of the company stock.
Largest 10 shareholders include PRIMECAP MANAGEMENT CO/CA/ (8.3M shares), BAKER BROS. ADVISORS LP (6.5M shares), BlackRock Inc. (6.27M shares), RA CAPITAL MANAGEMENT, L.P. (5.68M shares), GOLDMAN SACHS GROUP INC (5.19M shares), FEDERATED HERMES, INC. (3.89M shares), STATE STREET CORP (3.27M shares), VANGUARD GROUP INC (2.93M shares), NEA Management Company, LLC (2.91M shares), and Polar Capital Holdings Plc (2.25M shares).
This table shows the top 116 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.